This paper describes an updated literature search for clinical studies of erlotinib, gefitinib and other EGFR TKIs in patients with EGFR mutation-positive NSCLC, and reports the results of a pooled analysis of erlotinib, gefitinib and chemotherapy, with the aim of providing updated median pooled progression-free survival (PFS) values. This evidence concerns the gene EGFR and non-small cell lung carcinoma.